The estimated Net Worth of Karen Flynn is at least $4.92 Million dollars as of 10 January 2022. Ms Flynn owns over 2,472 units of Catalent stock worth over $1,981,087 and over the last 12 years she sold CTLT stock worth over $1,791,257. In addition, she makes $1,146,522 as Chief Commercial Officer at Catalent.
Ms has made over 11 trades of the Catalent stock since 2013, according to the Form 4 filled with the SEC. Most recently she sold 2,472 units of CTLT stock worth $288,334 on 10 January 2022.
The largest trade she's ever made was exercising 20,458 units of Catalent stock on 7 August 2018 worth over $477,285. On average, Ms trades about 716 units every 30 days since 2012. As of 10 January 2022 she still owns at least 33,223 units of Catalent stock.
You can see the complete history of Ms Flynn stock trades at the bottom of the page.
Karen A. Flynn is the Chief Commercial Officer at Catalent.
As the Chief Commercial Officer of Catalent, the total compensation of Ms Flynn at Catalent is $1,146,522. There are 9 executives at Catalent getting paid more, with John Chiminski having the highest compensation of $8,514,990.
Ms Flynn is 58, she's been the Chief Commercial Officer of Catalent since . There are 9 older and 17 younger executives at Catalent. The oldest executive at Catalent Inc. is Rolf Classon, 75, who is the Independent Director.
Karen's mailing address filed with the SEC is 9100 SOUTH HILLS BLVD, , BROADVIEW HEIGHTS, OH, 44147.
Over the last 10 years, insiders at Catalent have traded over $2,686,980,380 worth of Catalent stock and bought 123,000 units worth $5,376,345 . The most active insiders traders include Management Associates V L.L..., Peter Zippelius, and Frank A Damelio. On average, Catalent executives and independent directors trade stock every 17 days with the average trade being worth of $22,866,018. The most recent stock trade was executed by Ricky Hopson on 2 August 2024, trading 662 units of CTLT stock currently worth $39,429.
catalyst + talent. our name combines these ideas. from drug and biologic development services to delivery technologies to supply solutions, we are the catalyst for your success. with over 80 years of experience, we have the deepest expertise, the broadest offerings, and the most innovative technologies to help you get more molecules to market faster, enhance product performance and provide superior, reliable manufacturing and packaging results. catalent develops. with our broad range of expert services we drive faster, more efficient development timelines to help you take more molecules to market and create more effective products. catalent delivers. as the world leader in drug delivery innovations, we have a proven record of enhancing bioavailability, solubility and permeability, improving ease and route of administration, and increasing patient compliance for better treatments. catalent supplies. globally positioned to serve all your manufacturing and commercial packaging needs, we p
Catalent executives and other stock owners filed with the SEC include: